Galapagos NV - ADR (OQ:GLPG)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Feb 22, 2024 04:01 pm ET

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the close of an oversubscribed $80 million...

Jan 27, 2022 07:35 am ET

Thinking about buying stock in Aridis Pharmaceuticals, Galapagos, Qualtrics, Clean Energy Fuels, or Mattel?

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDS, GLPG, XM, CLNE, and MAT.

Mar 03, 2021 02:20 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

NEW YORK, March 3, 2021 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Feb 19, 2021 12:05 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Feb 10, 2021 09:00 am ET

Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF

Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies. Detailed data of the ISABELA studies will be presented at future medical meetings.

Dec 15, 2020 04:15 pm ET

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This announcement follows a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA.

Dec 12, 2020 06:50 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV (“Galapagos” or the “Company”) (NASDAQ: GLPG). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...

Dec 10, 2020 04:17 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

NEW YORK, Dec. 10, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Dec 10, 2020 04:17 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Nov 02, 2020 04:01 pm ET

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the application for a new indication to the approved license for filgotinib 200 mg, an oral JAK1 preferential inhibitor, has been validated and is now under evaluation by the European Medicines Agency (EMA). The proposed indication is for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Oct 12, 2020 09:15 am ET

Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis (UC). The data from the randomized, double-blind, placebo-controlled, Phase 2b/3 SELECTION trial showed that a significantly higher proportion of patients treated with filgotinib 200 mg, versus placebo, achieved clinical remission at Week 10 and maintained remission through Week 58. In

Sep 25, 2020 01:00 pm ET

European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).1

Aug 29, 2020 07:37 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

Aug 25, 2020 10:45 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

Aug 20, 2020 05:28 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

Jul 24, 2020 08:10 am ET

Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Jyseleca® (filgotinib 200 mg and 100 mg tablets), an investigational, once-daily, oral, selective JAK1 inhibitor for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). The CHMP positive opinion is a scientific recommendation to t

Jun 05, 2020 04:01 pm ET

New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the double-blind, placebo-controlled, Phase 2 EQUATOR study and the EQUATOR-2 open-label extension study demonstrate filgotinib’s durable efficacy and consistent safety profile in people with active PsA, and showed rapid and sustained reductions in inflammatory biomarkers in patients with moderate to severe PsA. The new analyses were

Jun 04, 2020 01:29 am ET

Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis (RA). The data demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations. The new data are among 15 abstracts on filgotinib in RA that will be presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheum

May 20, 2020 04:03 pm ET

Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis (UC). Filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significa

Apr 16, 2020 02:12 am ET

Galapagos and Ryvu Announce Research Collaboration

MECHELEN, Belgium and KRAKOW, Poland, April 16, 2020 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) (NASDAQ: GLPG) and Ryvu Therapeutics S.A. (WSE: RVU) today announced a collaboration focused on the discovery and development of novel small molecule drugs in inflammation.

Nov 09, 2019 04:30 pm ET

New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the companies’ clinical research program evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active RA. The data demonstrate durable efficacy and safety results with filgotinib across multiple RA patient populations, from MTX-naïve patients to those who have had an inadequate response to two or more biologic disease-modifying antirheumatic drugs (bDMARDs). The analyses will be presented at the 2019 American College of

Oct 31, 2019 04:01 pm ET

Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that new data from across the companies’ inflammatory disease research and development program will be presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting in Atlanta from November 8-13. The companies will present 20 abstracts at this year’s meeting, including key data on the investigational medicine filgotinib in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), as well as real-world RA treatment outcomes and care.

Oct 16, 2019 04:00 am ET

HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Galapagos NV

HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest to Galapagos NV. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Galapagos NV.

Oct 10, 2019 06:00 pm ET

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year.

Aug 23, 2019 04:01 pm ET

Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019.

Aug 15, 2019 04:01 pm ET

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA).

Jul 25, 2019 04:02 pm ET

Strong clinical progress in H1 and transformative collaboration with Gilead announced

First half-year financial results: Group revenues of €108.5 million Operating loss of €97.6 million Net loss of €95.9 million Cash and cash equivalents on 30 June 2019 of €1,148 million Further development of our broad and deep pipeline:...

Jul 18, 2019 04:02 pm ET

Transparency notification

Mechelen, Belgium; 18 July 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian transparency legislation[1], Galapagos received a...

Jul 14, 2019 01:01 pm ET

GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION

- Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment - - Gilead Gains Access to Galapagos' Differentiated Drug Discovery Platform and Current and Future Pipeline Outside of Europe - - Investment Enables Galapagos...

Jul 02, 2019 01:01 am ET

GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR

Mechelen, Belgium; 2 July 2019; 07.00 CET; regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) today announced that at a recent pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company provided an...

Jun 20, 2019 04:02 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 20 June 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 208,310 new ordinary shares on 20 June 2019, for a...

Jun 17, 2019 04:01 pm ET

Transparency notification

Mechelen, Belgium; 17 June 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from The Capital Group Companies, Inc. Pursuant to Belgian transparency legislation[1], Galapagos...

Jun 11, 2019 01:01 am ET

Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

Mechelen, Belgium and Paris, France, 11 JUNE 2019, 07.00 CET - Servier and Galapagos NV (Euronext & NASDAQ: GLPG) completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule. ROCCELLA is a multi-regional,...

May 29, 2019 04:31 pm ET

GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)

-- Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions -- Foster City, Calif. and Mechelen, Belgium; May 29, 2019; 22.30 CET - Gilead Sciences, Inc. (NASDAQ: GILD)...

May 29, 2019 04:30 pm ET

Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain, on June 12-15, 2019. Among the abstracts to be presented are 24 week interim results from the ongoing FINCH 1 and FINCH 3 Phase 3 studies evaluating filgotinib in adults with rheumatoid arthritis.

Apr 25, 2019 04:02 pm ET

Galapagos reports on historic first quarter 2019

Key Q1 2019 results: Group revenues of €40.9 million Operating loss €53.2 million Net loss of €48.7 million End of first quarter cash and cash equivalents €1.2 billion Competitive safety and efficacy results with filgotinib in FINCH 1 and...

Apr 23, 2019 04:02 pm ET

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Novartis Pharma AG (SIX: NOVN-CH) announced today the...

Apr 10, 2019 05:03 pm ET

Galapagos creates new warrant plans

Mechelen, Belgium; 10 April 2019, 22.01 CET; regulated information -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 2,070,000 warrants under new warrant plans for the benefit of the employees, directors,...

Apr 04, 2019 05:00 am ET

Investor Expectations to Drive Momentum within Cisco, NanoString Technologies, Galapagos NV, A10 Networks, International Seaways, and Scholastic — Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cisco Systems, Inc. (NASDAQ:CSCO), NanoString Technologies, Inc....

Mar 31, 2019 04:04 pm ET

Publication of the annual report and invitation to the annual shareholders' meeting

Nomination of Mr. Peter Guenter for Galapagos' board of directors Mechelen, Belgium; 29 March 2019, 22.15 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2018. The annual...

Mar 28, 2019 05:23 pm ET

GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)

-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 CET; regulated...

Mar 28, 2019 05:08 pm ET

GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)

Mar 28, 2019 05:04 pm ET

Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients

regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 3, an ongoing, randomized, double-blind, active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis. FINCH 3 evaluated filgotinib in combination with methotrexate and as monotherapy in MTX-naïve patients. The study achieved its primary endpoint in the proportion of patients achieving an

Mar 28, 2019 05:03 pm ET

Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study

regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 1, an ongoing, randomized, double-blind, placebo- and active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis. FINCH 1 evaluated filgotinib versus adalimumab or placebo, on a stable background dose of methotrexate in patients with prior inadequate response to methotrexate. The study achieved its

Mar 28, 2019 05:02 pm ET

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS

-- Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone -- -- Filgotinib Safety Profile Consistent With Previously Reported Results -- Foster City, Calif....

Mar 28, 2019 05:02 pm ET

Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA)

regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today also announced interim safety information from four studies of the investigational compound filgotinib for the treatment of rheumatoid arthritis (RA). The data include 24 week results of the ongoing Phase 3 FINCH 1, 2, and 3 trials, and updated Week 156 safety data from the Phase 2b DARWIN 3 long term extension study in patients with RA.

Mar 28, 2019 05:01 pm ET

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY

-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response -- -- Significant Inhibition of...

Mar 28, 2019 07:00 am ET

New Research Coverage Highlights Norwegian Cruise Line, Devon Energy, Tenneco, COUPA SOFTWARE, Galapagos NV, and BMC Stock — Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH), Devon Energy Corporation...

Mar 20, 2019 05:02 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 20 March 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 149,370 new ordinary shares on 20 March 2019, for a...

Feb 21, 2019 04:02 pm ET

Firmly on our way to becoming a fully integrated biopharma company

Revenues doubled in 2018 Key 2018 clinical results: FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability TORTUGA and EQUATOR Phase 2 trials with...

Feb 07, 2019 01:31 am ET

Evotec and Galapagos enter into collaboration in the field of fibrosis

Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), and Galapagos NV (Euronext & NASDAQ: GLPG) today announced a global collaboration focused on a novel...

Jan 08, 2019 04:03 pm ET

Sands Capital reports 5.7% holding in Galapagos

Mechelen, Belgium; 8 January 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital Management, LLC. Pursuant to Belgian transparency legislation[1], Galapagos...

Jan 07, 2019 01:31 am ET

Galapagos starts first Phase 1 trial with Toledo compound

Novel target class with dual action in inflammatory disorders Discovered and validated on Galapagos' target discovery platform Fully owned and proprietary Mechelen, Belgium; 7 January 2019, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG)...

Jan 06, 2019 04:02 pm ET

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

Mechelen, Belgium; 6 January 2019, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with '1690 in IPF. NOVESA is...

Jan 04, 2019 04:02 pm ET

Fibrocor and Galapagos sign partnership in fibrosis

Mechelen, Belgium; 4 January 2019, 22.01 CET - Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel target for idiopathic pulmonary...

Dec 21, 2018 04:02 pm ET

Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; 21 December 2018, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019. Onno van de Stolpe, CEO, will present on Wednesday, January 9...

Dec 17, 2018 04:20 pm ET

Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Mechelen, Belgium; 17 December 2018, 22.15 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that it has dosed its first patient in the worldwide ISABELA Phase 3 program with autotaxin inhibitor GLPG1690 in IPF. "Today's news again...

Dec 06, 2018 07:50 am ET

Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Best Buy Co., Inc. (NYSE:BBY), News Corporation (NASDAQ:NWSA), Semtech...

Nov 27, 2018 04:23 pm ET

Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis

Mechelen, Belgium; 27 November 2018, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the FDA has granted GLPG1972/S201086 Fast Track designation for the treatment of patients with osteoarthritis (OA). The US Food and...

Nov 26, 2018 04:02 pm ET

Transparency notification

Mechelen, Belgium; 26 November 2018; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian transparency legislation[1], Galapagos...

Nov 23, 2018 04:02 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 23 November 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 30,800 new ordinary shares on 23 November 2018,...

Oct 31, 2018 05:02 pm ET

Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Mechelen, Belgium; 31 October 2018; 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF). PINTA is a...

Oct 29, 2018 07:25 am ET

Factors of Influence in 2018, Key Indicators and Opportunity within ICON, Robert Half International, CenterPoint Energy, Galapagos NV, Canadian Pacific Railway, and Mobile Mini — New Research Emphasiz

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICON PLC (NASDAQ:ICLR), Robert Half International Inc. (NYSE:RHI),...

Oct 24, 2018 04:04 pm ET

Hallmark third quarter 2018 and Annual R&D Update at Galapagos

First nine months financial results: Group revenues increased by €98.7 million to €205.1 million Operating loss decreased by €9.1 million to €53.5 million Net loss decreased by €41.7 million to €44.2 million Cash and cash equivalents on 30...

Oct 24, 2018 04:03 pm ET

Galapagos and AbbVie restructure CF collaboration

Mechelen, Belgium, Chicago, US; 24 October 2018; 22.02 CET; regulated information - Galapagos NV (Euronext NASDAQ: GLPG) and AbbVie, Inc (NYSE: ABBV) announce a restructuring of their cystic fibrosis (CF) alliance; AbbVie takes over all...

Oct 24, 2018 04:02 pm ET

Topline interim results of FALCON trial Part 1 in CF

Mechelen, Belgium; 24 October 2018; 22.01 CET; regulated information - Galapagos NV (Euronext NASDAQ: GLPG) announces topline interim results of Part 1 of the FALCON trial in cystic fibrosis (CF). The FALCON trial is a phase 1b, multi-center,...

Oct 22, 2018 01:16 pm ET

POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET

Phase 2 EQUATOR Data Demonstrating Efficacy in Psoriatic Arthritis Also Presented in a Plenary Session at 2018 ACR/ARHP Annual Meeting Chicago, October 22, 2018; 19.15 CET - Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext ...

Oct 22, 2018 01:15 pm ET

Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. The publication of the Phase 2 EQUATOR data also coincides with a plenary session presentation at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.

Oct 20, 2018 06:31 pm ET

PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING

-- FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life - Chicago, October 21, 2018 0.30 CET- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext ...

Oct 20, 2018 06:30 pm ET

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest

Oct 03, 2018 04:02 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 3 October 2018, 22.01 CET; regulated information - Galapagos NV (Euronext NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 135,485 new ordinary shares on 3 October 2018, for...

Sep 24, 2018 01:31 am ET

Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients

Mechelen, Belgium, September 24 2018, 07.30 CET - Galapagos NV (Euronext NASDAQ: GLPG) reports first dosing in the global ROCCELLA Phase 2 trial with GLPG1972/S201086 in knee osteoarthritis patients. Galapagos receives a €9 million milestone...

Sep 17, 2018 04:02 pm ET

Galapagos issues new shares as result of public offering

Mechelen, Belgium; 17 September 2018, 22.01 CET; regulated information - Galapagos NV (Euronext NASDAQ: GLPG) announces a share capital increase as a result of a public offering of American Depositary Shares. In accordance with Belgian...

Sep 17, 2018 04:02 pm ET

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million

Mechelen, Belgium, 17 September 2018, 22.01 CET, regulated information - Galapagos NV (Euronext NASDAQ: GLPG) announced today the closing of its underwritten public offering of 2,961,373 American Depositary Shares ("ADSs") at a price of $116.50...

Sep 13, 2018 04:03 pm ET

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Mechelen, Belgium and Planegg/Munich, Germany; 13 September 2018; 22.01 CET; Galapagos NV (Euronext NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today the initiation of a Phase 1 bridging study...

Sep 12, 2018 09:16 pm ET

Galapagos raises $300 million gross proceeds in a U.S. public offering

Mechelen, Belgium, 13 September 2018, 03.00 CET, regulated information - Galapagos NV (Euronext NASDAQ: GLPG) announced today the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form...

Sep 12, 2018 04:54 pm ET

Galapagos announces launch of proposed public offering

Mechelen, Belgium, 12 September 2018, 22.45 CET, regulated information - Galapagos NV (Euronext NASDAQ: GLPG) announced today that it intends to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the...

Sep 12, 2018 04:02 pm ET

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Mechelen, Belgium and Planegg/Munich, Germany; 12 September 2018; 22.01 CET; Galapagos NV (Euronext NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today the expiration of the waiting period under...

Sep 11, 2018 04:06 pm ET

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS

-- Filgotinib 100 mg and 200 mg Doses Achieved Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response to Biologic Agents -- -- Both Filgotinib Doses also Achieved All...

Sep 11, 2018 04:05 pm ET

Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response/intolerance to biologic agents, achieved its primary endpoint in the proportion of patients achieving an American College of Rheumatology 20 percent response (ACR20) at Week 12. Also at Weeks 12 and 24, the proportion of

Sep 06, 2018 01:01 am ET

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT

Foster City, Calif. and Mechelen, Belgium; September 6, 2018; 7.00 CET; Regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext NASDAQ: GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA...

Sep 06, 2018 01:00 am ET

Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint

Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV (Euronext & NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis (AS). In the study, patients treated with filgotinib achieved significantly greater improvements in AS Disease Activity Score (ASDAS), the primary endpoint, at Week 12, with a mean change from baseline of -1.5 versus -0.6 for

Aug 02, 2018 04:03 pm ET

Productive first half-year at Galapagos

First half-year financial results: Group revenues of €101.9 million Operating loss of €65.8 million Net loss of €59.1 million Cash and cash equivalents on 30 June 2018 of €1,066.8 million Substantial progress in the pipeline: Reported...

Jul 19, 2018 01:16 am ET

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Exclusive global license agreement with Novartis on MOR106 MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic dermatitis (AtD) and potentially other indications Up-front payment of EUR 95 million (USD 111...

Jul 09, 2018 01:31 am ET

Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF

Mechelen, Belgium; 9 July 2018; 7.30 CET - Galapagos NV (Euronext NASDAQ: GLPG) announces the PINTA Phase 2 trial design with its GPR84 inhibitor GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF). PINTA is a randomized,...

Jun 26, 2018 04:02 pm ET

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients

Paris (France) and Mechelen (Belgium), 26 June 2018, 22.01 CET - Servier, an independent international pharmaceutical company, and Galapagos NV (Euronext NASDAQ: GLPG) announce the start of a global Phase 2 trial with S201086/GLPG1972 in knee...

Jun 20, 2018 04:02 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 20 June 2018, 22.01 CET; regulated information - Galapagos NV (Euronext NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 102,801 new ordinary shares on 20 June 2018, for a...

Jun 14, 2018 04:02 pm ET

Transparency notification

Mechelen, Belgium; 14 June 2018; 22.01 CET; regulated information - Galapagos NV (Euronext NASDAQ: GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian transparency legislation[1], Galapagos received a...

Jun 05, 2018 07:35 am ET

Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway — What Drives Growth in Today

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Galapagos NV (NASDAQ:GLPG), Cellectis S.A. (NASDAQ:CLLS), MediciNova, Inc....

May 30, 2018 04:02 pm ET

GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS

-- EQUATOR Achieves Primary Endpoint of ACR20 Response at Week 16 --

May 30, 2018 04:01 pm ET

Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20 percent improvement score (ACR20). There was an ACR20 response of 80 percent for filgotinib versus 33 percent for plac

May 20, 2018 02:31 pm ET

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Mechelen, Belgium; 20 May 2018; 20.30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces publication milestones on GLPG1690 in idiopathic pulmonary fibrosis (IPF). In addition to presenting three abstracts on investigational drug GLPG1690 at the American Thoracic Society Meeting (ATS)...

May 01, 2018 04:02 pm ET

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Mechelen, Belgium and Planegg/Munich, Germany; 1 May 2018; 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the first patient has been screened in IGUANA, a Phase...

Apr 27, 2018 01:31 am ET

Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018

Mechelen, Belgium; 27 April 2018, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) presents preclinical results showing broad beneficial effects on cartilage and bone with GLPG1972 in an osteoarthritis (OA) rat model at the Osteoarthritis Research Society International (OARSI)...

Apr 25, 2018 04:02 pm ET

Galapagos reports first quarter 2018 results

Key Q1 2018 results:

Apr 24, 2018 02:46 am ET

Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

Mechelen, Belgium; 24 April 2018; 08.45 AM CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of its first clinical trial with an investigational triple combination therapy in cystic fibrosis patients.

Apr 19, 2018 04:02 pm ET

Galapagos creates new warrant plan

Mechelen, Belgium; 19 April 2018, 22.01 CET; regulated information -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 1,585,000 warrants under new warrant plans for the benefit of employees, future employees, directors and a...

Apr 12, 2018 04:02 pm ET

Galapagos announces ISABELA Phase 3 program in IPF

Mechelen, Belgium; 12 April 2018, 22.01 CET - Galapagos announces the design of a worldwide Phase 3 program, based on feedback from the FDA and EMA, to evaluate GLPG1690 in patients with idiopathic pulmonary fibrosis. The planned ISABELA Phase 3...

Apr 12, 2018 07:55 am ET

Factors of Influence in 2018, Key Indicators and Opportunity within Galapagos NV, BanColombia S.A, Fanhua, Landec, Green Brick Partners, and Core-Mark Holding — New Research Emphasizes Economic Growth

NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Galapagos NV (NASDAQ:GLPG), BanColombia S.A. (NYSE:CIB),...

Mar 23, 2018 04:31 pm ET

Publication of the annual report and invitation to the annual shareholders' meeting

Mechelen, Belgium; 23 March 2018, 21.30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2017.

Mar 20, 2018 05:02 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 20 March 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.

Mar 15, 2018 07:45 am ET

Market Trends Toward New Normal in Golden Ocean Group, Redhill Biopharma, Galapagos NV, Crawford, Amphastar Pharmaceuticals, and 51job — Emerging Consolidated Expectations, Analyst Ratings

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Golden Ocean Group Limited (NASDAQ:GOGL), Redhill...

Feb 22, 2018 04:02 pm ET

Galapagos delivered in 2017

Key 2017 results:

Feb 17, 2018 04:01 am ET

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Mechelen, Belgium and Planegg/Munich, Germany; 17 February 2018; 10.00 CET -Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced the presentation of more detailed results of the Phase 1 study with the...

Jan 07, 2018 04:01 pm ET

Positive topline results with GLPG1972 in osteoarthritis patients

Mechelen, Belgium; 7 January 2018, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports positive preliminary topline results with a Phase 1b study in osteoarthritis (OA) patients in the United States.

Jan 02, 2018 04:02 pm ET

Update on progress in cystic fibrosis programs

Mechelen, Belgium; 2 January 2017, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) provided an update on several aspects of its cystic fibrosis (CF) programs: Galapagos started three new clinical studies, concluded the FLAMINGO study in CF patients, and...

Dec 18, 2017 01:31 am ET

Transparency notification

Mechelen, Belgium; 18 December 2017; 7.30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.

Dec 14, 2017 04:02 pm ET

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

Equity lock-up and standstill arrangement between the companies to expire on 31 December 2017

Dec 11, 2017 04:02 pm ET

Transparency notification

Mechelen, Belgium; 11 December 2017; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Fidelity Management & Research (FMR) LLC.

Dec 11, 2017 01:31 am ET

Galapagos to enter NASDAQ Biotech Index

Mechelen, Belgium; 11 December 2017; 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces that it will be included in NASDAQ Biotech Index on NASDAQ, effective 18 December 2017.

Nov 23, 2017 04:02 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 23 November 2017, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.

Nov 21, 2017 04:02 pm ET

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Mechelen, Belgium; 21 November 2017; 22.01 CET -Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with a novel C2 corrector GLPG3221 for cystic fibrosis (CF). Galapagos receives a $10 million milestone payment from its collaboration...

Nov 19, 2017 04:02 pm ET

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

Mechelen, Belgium; 19 November 2017, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports positive topline results from its ALBATROSS Phase 2 study in cystic fibrosis patients with C1 corrector GLPG2222.

Nov 05, 2017 09:01 am ET

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

Galapagos presents data from DARWIN 3, other filgotinib studies and Galapagos' GLPG1972 at American College of Rheumatology Meeting 2017

Nov 02, 2017 02:32 am ET

Galapagos moving forward in CF programs at NACFC 2017

Ten posters and four oral presentations reflect progress toward triple combination therapy

Oct 26, 2017 04:02 pm ET

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

Substantial progress in R&D Inflammation: Studies with filgotinib started in uveitis and lupus membranous nephropathy IL-17C antibody MOR106 showed promising signs of activity in atopic dermatitis patients in Phase 1b study Fibrosis: Positive POC with GLPG1690 in IPF patients UK regulatory agency cleared path for submission of CF triple combination patient study in Q4 First nine months 2017 financial results Revenues €106.4 M, an increase of €41.3 M compared to 2016 Operating loss €62.6 M, an increase of €14.1 M compared to 2016 Cash on 30 September 2017 of €1...

Sep 21, 2017 04:01 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 21 September 2017, 22.00 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises....

Aug 09, 2017 04:02 pm ET

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Forced vital capacity (FVC) in lungs stabilized over the 12-week treatment period, placebo arm showed expected decline Functional respiratory imaging (FRI) confirms FVC data with statistical significance GLPG1690 was generally well tolerated First autotaxin inhibitor to show effect in IPF patient trial GLPG1690 expected to progress to late stage trial Webcast presentation of the results to be held tomorrow 10 August, 14.00 CET/8 AM EDT, +32 2 404 0659, access code 2084135; more call number info further down...

Jul 27, 2017 04:02 pm ET

Solid financials support R&D progress

...

Jul 27, 2017 04:01 pm ET

Servier licenses GLPG1972 in osteoarthritis from Galapagos

Mechelen, Belgium; Suresnes Cedex, France; 27 July 2017, 22.00 CET, regulated information - As a result of their research collaboration, Servier announces today that it has exercised its option to develop novel osteoarthritis molecule GLPG1972/S201086 from Galapagos NV (Euronext/NASDAQ: GLPG), thus obtaining global commercial rights outside the U.S. ...

Jun 20, 2017 04:01 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 20 June 2017, 22.00 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises....

May 17, 2017 04:01 pm ET

Galapagos creates new warrant plan

Mechelen, Belgium; 17 May 2017, 22.00 CET; regulated information -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,074,500 warrants under new warrant plans for the benefit of employees, future employees, directors and a consultant of the Company and its subsidiaries. ...

May 15, 2017 04:01 pm ET

Seven abstracts on filgotinib accepted by EULAR 2017

Mechelen, Belgium; 15 May 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces the acceptance of seven abstracts from several clinical and pre-clinical studies with the investigational agent filgotinib in rheumatoid and psoriatic arthritis, by the Annual European Congress of Rheumatology organized by the European League Against Rheumatism (EULAR) 2017, held in Madrid from 14-17 June. Following is a list of accepted abstracts:...

May 07, 2017 10:36 am ET

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

Mechelen, Belgium; 7 May 2017, 16.35 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces the presentation of three posters from the Phase 2 FITZROY study of the investigational agent filgotinib in Crohn's Disease, at Digestive Disease Week® (DDW[1]) 2017 in Chicago, IL USA, held from 6-9 May. More information can be found at www.ddw.org....

Apr 29, 2017 01:30 am ET

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Mechelen, Belgium; 29 April 2017, 7.30 CET -Galapagos NV (Euronext & NASDAQ: GLPG) announces presentation of pre-clinical pharmacology data with GLPG1972 at the Osteoarthritis Research Society International (OARSI) annual meeting today in Las Vegas, USA. ...

Apr 27, 2017 04:00 pm ET

Galapagos reports first quarter 2017 results

Key Q1 2017 results:...

Apr 25, 2017 04:00 pm ET

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Mechelen, Belgium; 25 April 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces a new Phase 2 Proof-of-Concept study investigating filgotinib and another investigational agent in cutaneous lupus erythematosus (CLE). This study is being led by filgotinib collaboration partner Gilead Sciences, Inc....

Apr 21, 2017 04:02 pm ET

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

Mechelen, Belgium; 21 April 2017, 22.01 CET; regulated information - Galapagos NV (Euronext: GLPG; Nasdaq: GLPG) announced today the closing of its underwritten public offering of 4,312,500 American Depositary Shares ("ADSs"), at a price of $90.00 per ADS, before underwriting discounts, for gross proceeds of €363.9 million. This includes the full exercise of the underwriters' option to purchase additional ADSs. All of the ADSs were offered by Galapagos. ...

Apr 21, 2017 04:02 pm ET

Galapagos announces capital increase

Mechelen, Belgium; 21 April 2017, 22.01 CET; regulated information - Galapagos NV (Euronext: GLPG; Nasdaq: GLPG) announces a share capital increase as a result of a public offering of American Depositary Shares....

Apr 17, 2017 10:10 pm ET

Galapagos raises $338 million gross proceeds in a U.S. public offering

Mechelen, Belgium, 18 April 2017, 04.10 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today the pricing of its U.S. public offering totaling $338 million gross proceeds of 3,750,000 new ordinary shares in the form of American Depositary Shares ("ADSs") at $90 per ADS, before underwriting discounts. ...

Apr 17, 2017 04:11 pm ET

Galapagos announces launch of proposed public offering

Mechelen, Belgium, 17 April 2017, 22.10 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it intends to offer and sell, subject to market and other conditions, $275 million of its ordinary shares in the form of American Depositary Shares (ADSs) in a U.S. public offering. ...

Mar 23, 2017 05:01 pm ET

Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings

Mechelen, Belgium; 23 March 2017 - Today Galapagos NV (Euronext & NASDAQ: GLPG) published its Annual Report for the financial year 2016. The annual report for the financial year 2016, including a review of figures and performance, is available online on http://reports.glpg.com/annual-report-2016/nl/ and can also be downloaded as PDF....

Feb 23, 2017 04:01 pm ET

Galapagos reports strong financial results and newsflow-rich pipeline

Key 2016 results:...

Feb 23, 2017 04:00 pm ET

Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451

Mechelen, Belgium; 23 February 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a Phase 1 study....

Jan 20, 2017 04:03 pm ET

Galapagos creates new warrant plan

Mechelen, Belgium; 20 January 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 150,000 warrants under a new warrant plan for the benefit of an employee of a subsidiary of the Company. ...

Jan 17, 2017 04:05 pm ET

Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer

Mechelen, Belgium; 17 January 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces the appointment of Dr. Walid Abi-Saab to the role of Chief Medical Officer, beginning on 1 March 2017. ...

Dec 20, 2016 04:06 pm ET

SAPHIRA 1 topline shows competitive clinical results in G551D patients

First potentiator after Kalydeco®[1] to show comparable results in G551D patients GLPG1837 was generally well tolerated when dosed up to 500 mg twice daily for 14 days Statistically significant and dose dependent decreases in sweat chloride observed Clinical validation of in vitro predictive platform Webcast presentation tomorrow (21 Dec) at 15.00 CET/9 AM ET, www.glpg.com, + 32 2 404 0659, code 6588087...

Dec 08, 2016 04:03 pm ET

Start Phase 2b/3 study with filgotinib in ulcerative colitis

Mechelen, Belgium, Dec. 08, 2016 (GLOBE NEWSWIRE) -- First patient dosed triggers a $10 million milestone payment...

Nov 29, 2016 04:03 pm ET

Galapagos increases share capital through warrant exercises

Mechelen, Belgium, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Mechelen, Belgium; 29 November 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises....

Nov 28, 2016 04:03 pm ET

Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737

Mechelen, Belgium, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Triggers $10 million milestone payment in collaboration with AbbVie...

Nov 22, 2016 04:03 pm ET

Phase 3 study with filgotinib initiated in Crohn's disease

MECHELEN, Belgium, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) reports the first dosing of a patient in the DIVERSITY Phase 3 study with filgotinib in Crohn's disease (CD). The start of the DIVERSITY study triggers a $50 million milestone payment from Gilead. ...

Oct 27, 2016 04:09 pm ET

Robust progress in Q3 2016

Financial results of the first nine months: Group revenues increased by €17.8 M to €65.0 M Operating loss reduced by €14.8 M to €48.5 M End of third quarter cash €938.8 M Progress in R&D: Start FINCH Phase 3 program with filgotinib in rheumatoid arthritis (RA) Successful completion of regulatory consultations for filgotinib in inflammatory bowel disease (IBD) Endoscopic improvements with filgotinib consistent with clinical remission rates in Crohn's disease (CD) Improvements in FEV1 with GLPG1837 in cystic fibrosis...

Oct 27, 2016 01:38 am ET

Galapagos to present progress in CF programs at NACFC 2016

MECHELEN, Belgium, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) will present the following plenary presentations and posters at the North American Cystic Fibrosis Conference (NACFC) in Orlando this week:...

Oct 12, 2016 04:12 pm ET

Transparency notification - FMR LLC reaches 10% threshold

MECHELEN, Belgium, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Fidelity Management & Research (FMR) LLC....

Sep 29, 2016 01:40 am ET

MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis

Ongoing Phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis Favorable safety results shown in healthy volunteers receiving single ascending doses (SAD) in the study to date MOR106 first publicly disclosed antibody targeting IL-17C in clinical studies worldwide MECHELEN, Belgium and MARTINSRIED/MUNICH, Germany, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the first patient with atopic dermatitis was d...

Sep 27, 2016 04:04 pm ET

Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease

Global program to start in Q4'16 DIVERSITY Phase 3 study in Crohn's disease SELECTION Phase 2b/3 study in ulcerative colitis 100 mg and 200 mg once daily doses included MECHELEN, Belgium, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) reports the successful completion of discussions with the regulatory authorities in the US and Europe to initiate the DIVERSITY Phase 3 study in Crohn's disease and the SELECTION Phase 2b/3 study in ulcerative colitis with filgotinib. Both studies will investigate efficacy and safety of 100 mg and 200 mg filgoti...

Sep 25, 2016 08:20 pm ET

Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease

MECHELEN, Belgium, Sept. 25, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) reports that Dr Severine Vermeire, principal investigator of the FITZROY Phase 2 study with investigational agent filgotinib in Crohn's disease, will present endoscopic and other key findings from the study in an oral session during United European Gastroenterology Week (UEG Week) in Vienna, Oct. 15 - 19, 2016. The abstract for the talk is available online at www.ueg.eu/week/ . ...

Sep 19, 2016 04:10 pm ET

Galapagos increases share capital through warrant exercises

MECHELEN, Belgium, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises....

Sep 06, 2016 01:40 am ET

Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis

MECHELEN, Belgium, Sept. 6, 2016 (GLOBE NEWSWIRE) -- Galapagos (Euronext & NASDAQ: GLPG) announces today that the European Commission (EC) has granted GLPG1690 'orphan drug designation' for the treatment of patients with idiopathic pulmonary fibrosis (IPF). ...

Aug 22, 2016 04:09 pm ET

FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis

Three studies addressing a broad population of patients with active rheumatoid arthritis Filgotinib 100 mg and 200 mg, once daily dosing in males and females worldwide in combination- and as monotherapy MECHELEN, Belgium, Aug. 22, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) reports the initiation of the FINCH global Phase 3 program investigating the efficacy and safety of 100 mg and 200 mg filgotinib once daily, in rheumatoid arthritis (RA) patient populations, ranging from early stage to biologic-experienced patients. ...

Jul 29, 2016 04:08 pm ET

Galapagos receives transparency notification from Federated

MECHELEN, Belgium, July 29, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Federated Equity Management Company of Pennsylvania ....

Jul 28, 2016 04:20 pm ET

Focus on filgotinib and cystic fibrosis

First half-year financial results: Revenues €48.8 M, an increase of €11.9 M compared to H1 2015 Operating loss €24.3 M, an improvement of € 11.3 M compared to H1 2015 Cash on 30 June 2016 of €968.5 M Ruling for reduced tax rate on filgotinib income Solid execution of R&D programs Successful conclusion of regulatory discussions for filgotinib in rheumatoid arthritis Phase 3 program Expansion of cystic fibrosis collaboration with AbbVie Favorable topline Phase 1 results in cystic fibrosis and osteoarthritis ...

Jun 23, 2016 01:33 am ET

Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' Board of Directors

MECHELEN, Belgium, June 23, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) has the honor to invite its Shareholders, Warrant Holders, Directors and Statutory Auditor to its Special and Extraordinary Shareholders' Meetings that will be held on Tuesday 26 July 2016 at 2 pm CET at the offices of notary public Matthieu Derynck (Van Halteren, associated notaries public, Rue de Ligne 13, 1000 Brussels)....

Jun 15, 2016 01:36 am ET

Galapagos' R&D Update 2016

C1 corrector GLPG2222 for cystic fibrosis (CF) and GLPG1972 in osteoarthritis well-tolerated and no emerging safety signals observed in healthy volunteers GLPG1972 strongly reduces OA cartilage breakdown biomarker within two weeks New pre-clinical candidates GLPG2938 for idiopathic pulmonary fibrosis and GLPG2534 for atopic dermatitis Deep pipeline of inflammation, fibrosis, metabolic, and anti-infective programs based on novel mechanisms of action Building pipeline with the aim to initiate one Phase 3 program every two years and three clinical Proofs-of-Concept per year ...

Jun 09, 2016 01:34 am ET

Galapagos selected for AEX Index

MECHELEN, Belgium, June 9, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) announces that Euronext has selected Galapagos NV for inclusion in the AEX®1 Index on Euronext Amsterdam, effective 20 June 2016. Galapagos is the first biotechnology company ever to be included in the AEX Index....

Jun 01, 2016 04:05 pm ET

Galapagos creates new warrant plan

Mechelen, Belgium, June 1, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 865,000 warrants under new warrant plans for the benefit of employees, directors and an independent consultant of the Company and its subsidiaries. ...

May 25, 2016 04:04 pm ET

FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016

MECHELEN, Belgium, May 25, 2016 (GLOBE NEWSWIRE) -- Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at Digestive Disease Week (DDW1) 2016 in San Diego, CA, USA, held from 21-24 May. More information can be found at www.ddw.org ....

May 24, 2016 04:09 pm ET

Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)

FINCH Phase 3 studies to start in Q3'16 Three registration studies addressing a broad population of RA patients 100 mg and 200 mg once daily dosing in males and females world-wide Mechelen, Belgium, May 24, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext:GLPG) (NASDAQ:GLPG) reports the successful completion of the discussions with the regulatory authorities in the US and Europe and discloses the doses for the FINCH global Phase 3 program with filgotinib in RA. The FINCH program will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily, globally addressing a...

Ad blocking detected

Galapagos NV - ADR (OQ:GLPG)

Business Focus: Biotechnology & Medical Research